Synthesis and biological activity of derivatives of 1-bromo-17-azapentacyclo[6.6.5.02,7.09,14.015,19]nonadeca-2,4,6,9,11,13-heksaen-16,18-dione.

Authors

  • Bożena Kuran Department of Medical Chemistry, Medical University of Warsaw, 3 Oczki Str., 02-007 Warsaw, Poland Author
  • Mariola Krawiecka Department of Medical Chemistry, Medical University of Warsaw, 3 Oczki Str., 02-007 Warsaw, Poland Author
  • Szymon Rosołowski Department of Medical Chemistry, Medical University of Warsaw, 3 Oczki Str., 02-007 Warsaw, Poland Author https://orcid.org/0009-0004-7333-7963
  • Jerzy Kossakowski Department of Medical Chemistry, Medical University of Warsaw, 3 Oczki Str., 02-007 Warsaw, Poland Author
  • Ksenia Szymanek Department of Medical Microbiology, Medical University of Warsaw, 5 Chałubińskiego Str., 02-004 Warsaw, Poland Author https://orcid.org/0000-0003-4314-3522
  • Grażyna Młynarczyk Department of Medical Microbiology, Medical University of Warsaw, 5 Chałubińskiego Str., 02-004 Warsaw, Poland Author https://orcid.org/0000-0002-6360-2688

Keywords:

N-substituted imides, 1-bromo-17-azapentacyclo[6.6.5.02,7.09,14.015,19]nonadec-2,4,6,9,11,13-heksaen-16,18-dione, antibacterial activity

Abstract

We synthesized a series of eleven new derivatives of 1-bromo-17-azapentacyclo[6.6.5.02,7.09,14.015,19]nonadec-2,4,6,9,11,13-heksaen-16,18-dione and antibacterial activities in vitro was estimated towards Gram-positive, Gram-negative bacteria and yeast from the ATCC collection. We tried to perform modifications in order to maintain elements having influence on the biological activity. Despite it, in evaluated preliminary tests only two compounds (III–IV) showed activity towards  Staphylococcus  aureus and Candida albicans. Therefore, biological research will be executed for them in the nearest future. The main aim of the present investigation will be to assay the minimal inhibitory concentration (MIC), minimal bactericidal concentration (MBC) for these two tested compounds III and IV and tolerance of C. albicans standard and S. aureus strains, which occur as various phenotypes (MRSA, MSSA, VISA, hetero-VISA, VSSA).

References

1. Filho V.C., Pinheiro T., Nunes R.J., Yunes R. A.: Il Farmaco 1994, 49, 675-677

2. Zentz F., et al.: Il Farmaco 2002, 57, 421-426

3. Zentz F., et al.: Marine Biotechnology 2002, 4, 431-440

4. Jindal D.P., et al.: Il Farmaco 2005, 60, 283-290

5. Filho V.C., et al.: Il Farmaco 1998, 53, 55-57

6. Kossakowski J, Perliński M.: Acta Pol Pharm. 2001, 58(4), 257-62

7. Doshi RK, Patel G, Mackay R, Wallach F.:Mt Sinai J Med. 2009, 76(1), 84-94. Review.

8. Lass-Flörl C.: Mycoses. 2009, 52(3), 197-205. Review.

9. Clinical and Laboratory Standards Institute. Antimicrobial Susceptibility testing (M100-S16). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard seventh edition (M7-A7). Performance standarts for antimicrobial disc susceptibility test approved standard-ninth edition (M2-A9). Clinical and Laboratory Standards Institute, Wayne, Pa, 2006.

Downloads

Published

2010-12-30

Issue

Vol. 23 No. 4 (2010): Annales UMCS, Pharmacia, Sectio DDD, Volume XXIII

Section

Artykuły

License

Copyright (c) 2010 Authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.